About the Company
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BMRN News
BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN) is a fast-growing pharmaceutical company focused on the development and ...
Biomarin Pharmaceutical Inc BMRN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 Biomarin Pharmaceutical Inc Earnings Call
Alexander Hardy; President, CEO & Director; BioMarin Pharmaceutical Inc. Brian R. Mueller; CFO & Executive VP; BioMarin Pharmaceutical Inc. Henry J. Fuchs; President ...
Miracle growth: Discover the biotech stock behind decades of jaw-dropping returns
Discover how this miracle growth biotech company is tackling rare genetic diseases with its innovative therapies.
Biomarin Pharmaceutical Inc. Q4 Earnings Summary
(RTTNews) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN): Earnings: $20.38 million in Q4 vs. -$0.25 million in the same period last year. EPS: $0.11 in Q4 vs.
Biomarin Pharmaceutical Stock (NASDAQ:BMRN), Quotes and News Summary
Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc ...
BioMarin: Q4 Earnings Snapshot
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported fourth-quarter net income of $20.4 million, after reporting a loss in the same ...
Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight
Warning! GuruFocus has detected 3 Warning Sign with BMRN. On February 26, 2024, Biomarin Pharmaceutical Inc (NASDAQ:BMRN) filed its annual 10-K report, providing a detailed overview of its financial ...
BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript
To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, Inc., including expectations regarding BioMarin's ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript
BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.44. BMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Q4 2023 Biomarin Pharmaceutical Inc Earnings Call
Alexander Hardy; President, CEO & Director; BioMarin Pharmaceutical Inc. Brian R. Mueller; CFO & Executive VP; BioMarin Pharmaceutical Inc. Henry J. Fuchs; President of Worldwide Research & ...
Loading the latest forecasts...